Logistics & Transportation

. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the final part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, outlines how real-time AI signal sharing across supply chain partners can help pharma companies anticipate demand shifts, reduce shortages, and respond faster to pandemics and geopolitical disruptions.

How AI Ecosystems Could Transform Pharma Demand and Crisis Response

Articles

The acquisition expands ORBIS’ manufacturing capacity and technical expertise in reusable plastic pallets, lids, and trays, enabling faster design, prototyping, and production for pharma and broader supply chain applications.

ORBIS Acquires Robinson Industries to Boost Reusable Packaging and Thermoforming Capabilities

In the third part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, explains why independent verification, validation, and human decision-making must stay central, as AI accelerates data processing and operational workflows across pharma supply chains.

Human Oversight Remains Essential, as AI Expands in Pharma Manufacturing and Distribution

The deal strengthens Körber’s SAP supply chain and digital manufacturing consulting portfolio, extends its global footprint, and creates Körber Stellium to deliver end-to-end supply chain and software solutions.

Körber Purchases Majority Stake in Stellium to Grow Global SAP Supply Chain Consulting Services

Podcasts

In today’s Pharma Pulse, a new national survey exposes the depth of America’s prescription access crisis, while AstraZeneca and Eli Lilly commit billions of dollars to next-generation weight-loss therapies and domestic manufacturing.

Pharma Pulse: The Access Gap

A professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business.

Despite steady growth since the Drug Quality and Security Act, outsourcing facilities remain constrained in scale and scope, offering targeted mitigation rather than systemic relief for persistent shortages.

Have 503B Outsourcing Facilities Truly Reduced US Drug Shortages?

The acquisition strengthens M&D’s specialty portfolio, broadens access to plasma-derived therapies, and supports phased integration focused on regulatory compliance.

Morris & Dickson Acquires Prodigy Health to Expand Specialty and Plasma Distribution Capabilities

In today’s Pharma Pulse, global pharmaceutical production hits a surge as manufacturers brace for US tariff shifts, while a new study reveals how smart speakers are slashing A1C levels for older adults.

Pharma Pulse: Manufacturing Front-Loading and the Smart Speaker Intervention

How direct-to-patient programming can transform the prescription journey for patients and manufacturers alike.

Why Direct-to-Patient Is the Pharma Industry’s Next Power Move

In today’s Pharma Pulse, AbbVie joins TrumpRx, shingles vaccines reveal a longevity boost, and HER2 therapies break new ground in cancer treatment.

Pharma Pulse: Navigating the New Era of Healthcare

The company will participate in the Trump administration’s direct-to-patient drug platform, while committing $100 billion to US R&D and manufacturing.

AbbVie Joins TrumpRx in Exchange for Tariff Relief and Pricing Flexibility

In the final part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, explains that with plant buildouts and validation requiring three to five years, today’s reshoring momentum reflects near-term policy pressures, but global demand and overseas biosimilar growth will ultimately shape the industry’s next phase.

Pharma’s US Manufacturing Push Faces a Long Investment Horizon

In today’s Pharma Pulse, Novartis expands its US radioligand footprint, and 15,000 New York City nurses go on strike.

Pharma Pulse: Precision Cancer Care

The pharma giant will invest in a 35,000-square-foot RLT manufacturing site in Winter Park, FL as part of its $23 billion US infrastructure expansion.

Novartis to Build Fourth US Radioligand Therapy Facility to Strengthen Supply Chain

In the third part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, shares how automatic contract adjustments tied to labor, energy, and inflation—combined with the critical role of supply reliability—allow the company to pass through limited surcharges while maintaining strong client relationships.

Managing Tariff-Driven Cost Increases Without Disrupting Customers

In today’s Pharma Pulse, Amazon Pharmacy launches Novo's first oral Wegovy pill with transparent cash pricing, Johnson & Johnson triples down on North Carolina manufacturing, and new clinical data links medical debt to rising eviction risks.

Pharma Pulse: Amazon Pharmacy Sells Oral Wegovy, J&J’s Billion-Dollar Hub, and the Debt-Housing Crisis

In the second part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, describes how from FDA validation to dual-site redundancy and reshoring momentum, the expansion of US capacity is a competitive advantage for pharma clients navigating increasingly complex global supply chains.

Why US-Based Manufacturing Is Becoming a Strategic Imperative for Biopharma

In today’s Pharma Pulse, Johnson & Johnson secures a major tariff deal by joining the federal drug discount portal, while new data warns that missing early infant shots is the leading predictor of skipped MMR vaccines.

Pharma Pulse: J&J Enters TrumpRx and the Red Flags in Pediatric Vaccines

The pharma giant becomes the latest manufacturer to participate in the Trump Administration’s direct-to-patient pricing platform, aligning US drug costs with European benchmarks while reinforcing its domestic manufacturing investments.

Johnson & Johnson Joins TrumpRx to Lower Drug Prices, Secures Tariff Exemption

In the first part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, explains how near-term tariff pressures are creating short-term headwinds while accelerating longer-term investment in regional manufacturing footprints—especially in the US.

Tariffs Nudge Pharma Toward Localization, but Supply Chains Can’t Shift Overnight

In today’s Pharma Pulse, the FDA issues two high-stakes priority vouchers for cholesterol and cancer therapies, GSK leverages genomic data to refine drug targets, and DHL completes a one-million-square-foot logistics center of excellence.

Pharma Pulse: FDA Fast-Tracks Merck Blockbusters, GSK’s Precision Data Bet, and DHL’s Massive PA Hub

A new Foreign Trade Zone–enabled facility in Annville strengthens the company’s temperature-controlled, compliant logistics capabilities, while accelerating customs processing and last-mile healthcare delivery.

DHL Supply Chain Opens 1-Million-Square-Foot Life Sciences Distribution Center in Pennsylvania, Expanding Healthcare Logistics Footprint

Merck’s decision to shutter its Riverside, PA antibiotic API facility underscores how decades of cost-driven optimization have eroded domestic manufacturing of essential medicines—exposing systemic vulnerabilities in US drug supply resilience that markets alone are unlikely to fix.

What the Closure of a Single Plant Reveals About US Drug Resilience

The sustainable packaging company relocates its branded foam production to a more expansive Lansing site, boosting capacity, efficiency, and support for growing demand in the life science market.

TemperPack Expands Michigan Footprint With Larger Green Cell Foam Manufacturing Facility

In the final part of her Pharma Commerce video interview, Tina Martinez, vice president and head of global products and solutions at Cencora, explains how streamlining clinical supply services, reducing fragmentation, and piloting data-driven tools like real-time adherence tracking are translating innovation into quantifiable efficiency, visibility, and commercial impact for manufacturers worldwide.

How Integrated Solutions Deliver Measurable Value for Pharma Manufacturers

In the second part of her Pharma Commerce video interview, Tina Martinez, vice president and head of global products and solutions at Cencora, outlines a customer-first approach to partnering with pharmaceutical manufacturers—centered on active listening, early problem validation, and iterative piloting—to co-develop scalable solutions that support late-stage clinical programs through commercial launch.

How Co-Creation Drives Successful Pharma Supply Chain Solutions

In the first part of his Pharma Commerce video interview, Arthur Axelrad, co-founder and CEO of Dispatch Science, discusses growing concerns around cargo theft and fraud in healthcare logistics—and how enhanced security features and platform innovation are helping manufacturers protect chain of custody and compliance.

Rising Cargo Theft Puts Healthcare Shipments Under Pressure

In today’s Pharma Pulse, Samsung Biologics enters the US market with a $280 million site acquisition, AstraZeneca secures a multi-billion-dollar cancer deal, and new research identifies occupational drivers of long COVID.

Pharma Pulse: US Manufacturing Expansion, Oncology Partnerships, and Workplace Health

The South Korea–based CDMO acquires its first US manufacturing facility in Rockville, MD, expanding its global footprint and strengthening biologics capacity.

Samsung Biologics Enters US Manufacturing Market with $280M GSK Site Acquisition

Thani Jambulingam, PhD, professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business, describes why uncertainty around final tariff rules is forcing manufacturers into a wait-and-see position.

Trade & Channel Strategies 2025: Waiting, Watching, and Reshoring

In today’s Pharma Pulse, major pharma players commit to most-favored-nation pricing, as DHL bolsters West Coast logistics for temperature-sensitive drugs.

Pharma Pulse: TrumpRx Gains Nine New Pharma Partners; DHL Expands LAX Cold Chain Hub

The CDMO’s latest GMP-qualified line strengthens sterile manufacturing scalability.

Alcami Brings Third Sterile Fill-Finish Line Online, Expanding Clinical-to-Commercial Capacity

In a discussion on global trade disruption, Thani Jambulingam, PhD, professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business, explains why pharmaceutical manufacturers must move beyond broad assumptions about tariffs and instead assess trade risk at the individual product level. 

Trade & Channel Strategies 2025: Why Product-Level Strategy Matters More Than Ever

In today’s Pharma Pulse, Novartis and Moderna anchor a domestic manufacturing surge, while AI-driven biomarker discovery and physician well-being reshape the future of clinical care.

Pharma Pulse: Onshoring Investments and the AI Frontier

The pharmaceutical giant’s new 700,000-square-foot hub aims to onshore production of key medicines and strengthen the US drug supply chain.

Novartis’ $23 Billion Manufacturing Investment Anchors Industry Shift Toward US Onshoring

CoverMyMeds’ Megan Wetzel unpacks the forces behind rising specialty spend,  the real impact of access barriers, and how field reimbursement teams help providers guide patients through today’s fragmented system.

Why Specialty Drugs Dominate Spending, and the Frontline Roles Shaping Patient Access

A principal solutions architect and supply chain analyst with FourKites.

AI-powered control towers and digital twins are emerging as essential tools 
to prevent costly supply chain failures and restore operational reliability.

How AI Control Towers and Digital Twins Can Restore Pharmaceutical Profit Margins

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.

Pharma Pulse: ACA Subsidy Gridlock Spurs Cost Crisis, as Lilly’s Retatrutide Delivers Positive Results in Phase III Trial

The entrepreneur urges the Trump administration to eliminate costly FDA generic drug fees, part of a broader push to scale domestic production, address shortages, and challenge PBM-driven pricing models.

Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion

In the first part of his Pharma Commerce video interview, Ed Schoonveld, value and access advisor for Schoonveld Advisory and author of The Price of Global Health, explains that affordability is only one pathway to securing a voucher—and reducing list prices isn’t the only way to demonstrate value.

Manufacturing & Packaging